CLYM
Climb Bio, Inc.
$8.74
-0.14
(-1.52%)
Mkt Cap
575.48M
Volume
933,850
52W Range
1.13-10.1
Sector
Healthcare
Beta
-0.20
EPS (TTM)
-0.89
P/E Ratio
-4.53
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (59.85M) | (73.90M) | (35.12M) | (45.24M) | (47.48M) | (20.67M) | (6.55M) |
| EPS | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 |
| Free Cash Flow | (54.54M) | (15.56M) | (20.60M) | (37.37M) | (36.07M) | (14.10M) | (5.01M) |
| FCF / Share | -0.80 | -0.32 | -0.76 | -1.42 | -2.94 | -1.21 | -0.43 |
| Operating CF | (54.36M) | (15.56M) | (20.60M) | (37.37M) | (36.07M) | (14.10M) | (5.01M) |
| Total Assets | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M | 24.63M | 21.39M |
| Total Debt | 541,000 | 532,000 | 349,000 | 480,000 | 0 | 0 | 0 |
| Cash & Equiv | 35.69M | 87.23M | 93.11M | 43.59M | 46.92M | 20.49M | 21.22M |
| Book Value | 160.47M | 211.88M | 107.60M | 128.72M | 167.20M | 21.57M | 20.61M |
| Return on Equity | -0.37 | -0.35 | -0.33 | -0.35 | -0.28 | -0.96 | -0.32 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (17.52M) | (12.89M) | (8.67M) | (20.78M) | (8.42M) | (8.89M) | (54.89M) | (1.70M) | (3.64M) | (3.97M) | (5.22M) | (22.29M) |
| EPS | -0.26 | -0.19 | -0.13 | -0.31 | -0.13 | -0.13 | -1.81 | -0.06 | -0.13 | -0.15 | -0.19 | -0.84 |
| Free Cash Flow | (15.63M) | (12.25M) | (11.22M) | (15.43M) | (5.52M) | (7.55M) | (667,000) | (1.82M) | (947,000) | 3.49M | (7.96M) | (15.18M) |
| FCF / Share | -0.23 | -0.18 | -0.17 | -0.23 | -0.09 | -0.11 | -0.02 | -0.07 | -0.03 | 0.13 | -0.30 | -0.57 |
| Operating CF | (15.63M) | (12.14M) | (11.15M) | (15.43M) | (5.52M) | (7.55M) | (667,000) | (1.82M) | (947,000) | 3.49M | (7.96M) | (15.18M) |
| Total Assets | 167.74M | 182.30M | 192.39M | 200.74M | 217.19M | 222.20M | 226.02M | 109.33M | 110.47M | 112.73M | 116.27M | 122.08M |
| Total Debt | 541,000 | 580,000 | 639,000 | 474,000 | 532,000 | 58,000 | 100,000 | 225,000 | 349,000 | 459,000 | 585,000 | 687,000 |
| Cash & Equiv | 35.69M | 25.80M | 22.68M | 29.02M | 87.23M | 146.18M | 223.14M | 105.03M | 93.11M | 57.35M | 25.29M | 34.44M |
| Book Value | 160.47M | 177.00M | 185.76M | 193.38M | 211.88M | 218.78M | 222.28M | 106.38M | 107.60M | 109.74M | 112.50M | 116.86M |
| Return on Equity | -0.11 | -0.07 | -0.05 | -0.11 | -0.04 | -0.04 | -0.25 | -0.02 | -0.03 | -0.04 | -0.05 | -0.19 |
CLYM News
Climb Bio, Inc. Announces $110.0 Million Private Placement
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio to Present at Upcoming Investor Conferences